Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up
Authors:
- Roman TremmelRoman Tremmel
- Filippa SchreeckFSFilippa Schreeck
- Simon JaegerSJSimon Jaeger
- Severin SchrickerSSSeverin Schricker
- Elke SchaeffelerESElke Schaeffeler
- Svitlana IgelSISvitlana Igel
- Daniela SteinbergerDSDaniela Steinberger
- Jörg LatusJLJörg Latus
- Markus KettelerMKMarkus Ketteler
- Marc‐H. DahlkeMDMarc‐H. Dahlke
Open Access
- 11 October 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (1) , 241-254
Abstract
Pharmacogenomics (PGx) helps to explain variability in drug response, including adverse drug reactions. Functional variants in genes affecting drug absorption, distribution, metabolism, and excretion (ADME) have been described. Despite PGx guidelines (e.g., CPIC and DPWG) enabling genotype‐guided drug and dose selection, preemptive implementation remains challenging due to various issues including standardized result communication and integration into electronic health record (EHR) systems. We implemented PGx testing as well as drug–drug interaction (DDI) screening in a German academic hospital and assessed their impact on physicians, general practitioners (GPs), and patients. A novel PGx workflow was established using a 60‐genetic variant panel. CPIC/DPWG guideline‐based PGx reports were integrated into the EHR system and provided as a mobile and web application for patients through a genetic information system. Medication profiles and questionnaires evaluated PGx‐based decisions 3 months post‐discharge. Among 255 patients, 95% had at least one actionable PGx variant, most commonly affecting statins, 5‐fluorouracil, irinotecan, and pantoprazole. Actionable recommendations were provided in 21.5%, with hospital physicians modifying treatment subsequently in 75.5%. We identified 57 clinically significant DDIs, including PGx drugs in 21%. GPs maintained optimized treatment in 77% of those patients with a medication change initiated during hospitalization. One in 10 patients discussed results with their GPs. GPs favored PGx for future prescriptions and requested training. We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.Keywords
This publication has 49 references indexed in Scilit:
- Pharmacogenomics in the UK National Health Service: Progress towards implementationBritish Journal of Clinical Pharmacology, 2025
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor AntidepressantsClinical Pharmacology & Therapeutics, 2023
- Pharmacogenomic Clinical Decision Support: A Scoping ReviewClinical Pharmacology & Therapeutics, 2022
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal SymptomsClinical Pharmacology & Therapeutics, 2022
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 UpdateClinical Pharmacology & Therapeutics, 2022
- Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 UpdateClinical Pharmacology & Therapeutics, 2018
- Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and ProjectsClinical Pharmacology & Therapeutics, 2018
- Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumClinical Pharmacology & Therapeutics, 2016
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline forCYP2D6genotype and use of ondansetron and tropisetronClinical Pharmacology & Therapeutics, 2016
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 updateClinical Pharmacology & Therapeutics, 2015